PRIMARY STUDY
Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Proceduresv
Key Findings: Using the biomarker liver-type fatty acid-binding protein (L-FABP) during cardiovascular procedures could provide more accurate and earlier identification of early kidney compromise due to iodinated contract exposure.
Type of Study: Clinical Trial
Study Sample Size: 154
Study Result: Positive
Study Location(s): Japan, United States
Year of Pub: 2022
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
